Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Signatory: Julian Babarczy, Chairman (Dated April 29, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a procedural filing to incorporate exhibits by reference into existing registration statements (Forms S-8 and F-3) rather than a financial results report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document. The filing primarily announces the submission of a Notice of General Meeting/Proxy Form (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the incorporation of the Notice of General Meeting/Proxy Form into the company's registration statements.
Investor Verification Checklist
- Verify the details of the General Meeting and Proxy Form referenced in Exhibit 99.1.
- Confirm the status of the Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076) into which this report is incorporated.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.